# BISCAY (NCT02546661)

> Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

No report yet. It can be ordered.

- Drugs tested: durvalumab plus fexagratinib (AZD4547); durvalumab plus olaparib; durvalumab plus adavosertib (AZD1775)

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02546661
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Muscle Invasive Bladder Cancer
- Interventions: AZD4547; MEDI4736; Olaparib; AZD1775; Vistusertib; AZD9150; Selumetinib
- Enrollment: 117
- Primary outcome: Module A: The frequency and nature of adverse events related to AZD4547 monotherapy.
- Primary outcome: Module A: The frequency and nature of adverse events related to the combination of intravenous MEDI4736 (durvalumab) and oral AZD4547.
- Primary outcome: Module B: The frequency and nature of adverse events related to the combination of intravenous MEDI4736 (durvalumab) and oral olaparib.
- Primary outcome: Module C: The frequency and nature of adverse events related to intravenous MEDI4736 (durvalumab) when given in combination with oral AZD1775.
- Primary outcome: Module D: The frequency and nature of adverse events related to intravenous MEDI4736 (durvalumab) monotherapy.
- Primary outcome: Module E: The frequency and nature of adverse events related to intravenous MEDI4736 (durvalumab) when given in combination with oral vistusertib.
- Primary outcome: Module F: The frequency and nature of adverse events related to the combination of intravenous MEDI4736 (durvalumab) and intravenous AZD9150.
- Primary outcome: Module G: The frequency and nature of adverse events related to intravenous MEDI4736 (durvalumab) when given in combination with oral selumetinib.
- Primary outcome: All Modules: Change from baseline in clinical chemistry parameters.
- Primary outcome: All Modules: Change from baseline in haematology parameters.
- Primary outcome: All Modules: Change from baseline in urinalysis results.
- Primary outcome: All Modules: Change from baseline in vital signs.
- Primary outcome: All Modules: Change from baseline in physical examination findings.
- Primary outcome: All Modules: Change from baseline in ECG findings.
- Primary outcome: All Modules: Change from baseline in ejection fraction determined by assessing ECHO/MUGA scans.
- Primary outcome: All Modules: Change from baseline in coagulation parameters
- Primary outcome: All Modules: Change from baseline in lipid profile

## Indexed commentary on BISCAY so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 21 posts on X
- 1 podcast episode

## Order

Deep, $1,950 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=biscay-nct02546661

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02546661", "email": "<work email>"}; the inbox owner confirms by the emailed link.